Chai Discovery

Company profile

About Chai Discovery

Chai Discovery is an AI-driven drug discovery company that develops frontier models and computational tools to predict and reprogram interactions between molecules. The company's mission is to transform biology from a scientific practice into an engineering discipline, enabling rational drug design where therapeutic candidates can be generated computationally and ready for IND-enabling studies. Their flagship technology, Chai-2, represents a breakthrough in de novo antibody design, capable of designing full-length, drug-like monoclonal antibodies (mAbs) with atomic precision. The platform achieves double-digit success rates for antibodies and over 50% success rates for miniproteins, allowing researchers to bypass traditional high-throughput screening. Chai-2 can target challenging proteins including GPCRs and membrane proteins, design for specific epitopes, handle post-translational modifications, and control for species specificity. The company has established major partnerships with leading pharmaceutical companies including Eli Lilly and Pfizer. Chai Discovery's technology addresses traditionally "hard to drug" targets and has demonstrated sub-angstrom level structural accuracy validated through cryo-EM studies. The company serves pharmaceutical companies, biotechnology firms, and academic researchers working on biologics discovery and therapeutic development.

Company description · Chai Discovery official website